Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act

This cohort study assesses rates at which orphan drugs approved by the US Food and Drug Administration were also approved for supplemental (follow-on) indications.

Detalles Bibliográficos
Autores principales: Chambers, James D., Clifford, Katherine A., Enright, Daniel E., Neumann, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427936/
https://www.ncbi.nlm.nih.gov/pubmed/37581890
http://dx.doi.org/10.1001/jamanetworkopen.2023.29006
_version_ 1785090355140493312
author Chambers, James D.
Clifford, Katherine A.
Enright, Daniel E.
Neumann, Peter J.
author_facet Chambers, James D.
Clifford, Katherine A.
Enright, Daniel E.
Neumann, Peter J.
author_sort Chambers, James D.
collection PubMed
description This cohort study assesses rates at which orphan drugs approved by the US Food and Drug Administration were also approved for supplemental (follow-on) indications.
format Online
Article
Text
id pubmed-10427936
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-104279362023-08-17 Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act Chambers, James D. Clifford, Katherine A. Enright, Daniel E. Neumann, Peter J. JAMA Netw Open Research Letter This cohort study assesses rates at which orphan drugs approved by the US Food and Drug Administration were also approved for supplemental (follow-on) indications. American Medical Association 2023-08-15 /pmc/articles/PMC10427936/ /pubmed/37581890 http://dx.doi.org/10.1001/jamanetworkopen.2023.29006 Text en Copyright 2023 Chambers JD et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Chambers, James D.
Clifford, Katherine A.
Enright, Daniel E.
Neumann, Peter J.
Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act
title Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act
title_full Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act
title_fullStr Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act
title_full_unstemmed Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act
title_short Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act
title_sort follow-on indications for orphan drugs related to the inflation reduction act
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427936/
https://www.ncbi.nlm.nih.gov/pubmed/37581890
http://dx.doi.org/10.1001/jamanetworkopen.2023.29006
work_keys_str_mv AT chambersjamesd followonindicationsfororphandrugsrelatedtotheinflationreductionact
AT cliffordkatherinea followonindicationsfororphandrugsrelatedtotheinflationreductionact
AT enrightdaniele followonindicationsfororphandrugsrelatedtotheinflationreductionact
AT neumannpeterj followonindicationsfororphandrugsrelatedtotheinflationreductionact

Ejemplares similares